Marker Therapeutics, Inc.

Monthly Archives: June 2015

TapImmune Reports Robust Immune Responses Generated in 19 of 20 Evaluable HER2/neu Breast Cancer Patients

Phase I Trial analyses shows safety and positive immune response data SEATTLE, June 23, 2015 /PRNewswire/ – TapImmune Inc. (TPIV) is pleased to report the completion of data analysis from patients treated in a Phase I clinical trial.
Read More

TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation

SEATTLE, June 2, 2015 /PRNewswire/ – TapImmune, Inc. (TPIV), a clinical stage cancer immunotherapy company, and its institutional investors have reached an agreement whereby the institutional investors will have the option to exercise their short term warrants to provide the Company up to $4.93M in near term funding, pending closing conditions and an effective S-1 registration statement.
Read More